Logo
x

Search

Subscribe Now

Severe

Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG...

  • November 11, 2021
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

  • October 8, 2021
AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Er...

  • August 2, 2021
Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis

Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthriti...

  • June 3, 2021
Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

  • June 2, 2021
PharmaShots Interview: Zealand Pharma's Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

PharmaShots Interview: Zealand Pharma's Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult...

  • April 28, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.